GO:0006369 termination of RNA polymerase II transcription: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006369 describes the biological process that completes production of a primary RNA polymerase II transcript, often called Pol II transcription termination.
• Termination is not a single event but a multi-step process involving elongation-complex remodeling, RNA 3'-end formation, and polymerase release.
• Two major termination routes are well established: polyadenylation-dependent termination and DNA-directed termination, including Integrator-dependent termination of snRNA genes.
• SPT5, SPT4, CPSF, CstF, XRN2, Integrator subunits, and the CTD of RPB1 are central factors in Pol II termination.
• Promoter-proximal termination can regulate gene expression during human cell type transitions, linking termination to developmental and disease biology.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal testing of termination factors in human cells.
Description
Termination of RNA polymerase II transcription (GO:0006369) is the biological process that completes the production of a primary RNA polymerase II transcript. It is the final stage of the transcription cycle, ensuring that RNA polymerase II (Pol II) stops RNA synthesis, releases the nascent transcript, and dissociates from DNA so that the template can be reused. Because termination is tightly coupled to RNA 3'-end processing, it influences the length, stability, and coding potential of mRNAs and non-coding RNAs. Researchers study GO:0006369 to understand how gene expression is bounded, how transcription units are defined, and how defects in termination contribute to disease. The process is conserved from yeast to humans, and genetic dissection of the RNA polymerase II transcription cycle has provided a framework for assigning functions to termination factors. Recent structural and kinetic studies have refined models of how Pol II is released, including DNA-directed and Integrator-dependent pathways.
termination of RNA polymerase II transcription At A Glance
| GO ID | GO:0006369 |
|---|---|
| GO term | termination of RNA polymerase II transcription |
| Ontology | biological_process |
| Synonym | RNA 3'-end formation by RNA polymerase II; RNA polymerase II transcription termination; RNA polymerase II transcription termination factor activity; transcription termination from Pol II promoter; transcription termination from RNA polymerase II promoter |
| Major function | Completes production of a primary RNA polymerase II transcript by stopping synthesis and releasing Pol II |
| Key machinery | Pol II elongation complex, SPT5/SPT4, CPSF/CstF, XRN2, Integrator, and the RPB1 CTD |
| Coupled processes | RNA 3'-end cleavage and polyadenylation, snRNA 3'-end formation, and transcription cycle recycling |
| Research relevance | Termination defects alter gene expression programs and are linked to developmental and disease phenotypes |
What Is GO:0006369?
In simple terms, GO:0006369 is the step that finishes a Pol II transcript. According to the QuickGO definition, it is a transcription termination process that completes the production of a primary RNA polymerase II transcript. This includes the events that stop RNA synthesis, free the RNA from the polymerase, and release Pol II from the DNA template. The term is a biological process and is distinct from initiation, elongation, and RNA processing, although it is functionally coupled to 3'-end formation.
Why Is termination of RNA polymerase II transcription Important in Cell Biology?
Termination of RNA polymerase II transcription is important because it defines the end of a transcription unit and prevents read-through into neighboring genes, which would otherwise disrupt gene expression. It is also required for efficient recycling of Pol II and for proper 3'-end formation of mRNAs and snRNAs. Because promoter-proximal termination can regulate transcription during human cell type transitions, the process is directly relevant to developmental gene regulation and to diseases in which transcriptional control is perturbed. Genetic dissection of the Pol II transcription cycle has shown that termination factors are separable from elongation factors, making GO:0006369 a tractable target for experimental perturbation.
• Defines the 3' boundary of Pol II transcription units and prevents transcriptional read-through.
• Couples transcription termination to RNA 3'-end cleavage and polyadenylation.
• Controls promoter-proximal termination, which can regulate gene expression during cell type transitions.
• Requires conserved elongation and termination factors such as SPT5 and SPT4.
• Involves DNA-directed termination mechanisms that release Pol II at specific DNA elements.
• Integrator-dependent termination is essential for snRNA gene expression.
• Termination rates can be measured kinetically at gene-specific resolution.
• Dysregulation of termination is linked to altered gene expression programs in disease.
• Provides a model system for dissecting the RNA polymerase II transcription cycle genetically.
• Offers CRISPR-tractable targets for functional studies of transcription termination.
What Happens During termination of RNA polymerase II transcription?
Elongation complex remodeling at the 3' end
In simple terms: Before transcription can stop, the polymerase and its associated factors must change into a termination-competent state.
As Pol II reaches the end of a transcription unit, the elongation complex undergoes remodeling that makes it competent for termination. SPT5 stabilizes RNA polymerase II and orchestrates transcription cycles, and its function is required for normal termination. Genetic dissection of the RNA polymerase II transcription cycle has identified separable roles for elongation and termination factors, indicating that remodeling is a distinct step.
RNA 3'-end cleavage and polyadenylation
In simple terms: The RNA is cut and given a poly(A) tail, which signals that the transcript is complete.
Termination of Pol II transcription is coupled to RNA 3'-end formation, including cleavage and polyadenylation of the primary transcript. The polyadenylation machinery, including CPSF and CstF, recognizes signals in the nascent RNA and triggers cleavage, which in turn promotes termination. This coupling ensures that only properly processed transcripts are completed.
Polymerase release and XRN2-dependent termination
In simple terms: After the RNA is cut, a nuclease degrades the leftover RNA still attached to the polymerase, causing the polymerase to let go.
In the polyadenylation-dependent model, cleavage of the nascent transcript generates a free 5' end that is degraded by XRN2, and this degradation is thought to promote Pol II release. The BOOM model summarizes evidence that termination involves multiple pathways and that polymerase release is a regulated event. Kinetic measurements of gene-specific Pol II elongation rates provide quantitative constraints on when and where release occurs.
DNA-directed termination
In simple terms: In some cases, the DNA sequence itself tells the polymerase to stop.
DNA-directed termination of RNA polymerase II transcription has been demonstrated in vitro and in mammalian cells. This pathway can release Pol II independently of polyadenylation signals and involves specific DNA elements that trigger termination. These findings expand the classical view of termination beyond RNA-processing-coupled models.
Integrator-dependent termination of snRNA genes
In simple terms: A specialized machine called Integrator stops the polymerase at small nuclear RNA genes.
Integrator is a multi-subunit complex that promotes termination of Pol II at snRNA genes. The structural basis of Integrator-dependent RNA polymerase II termination has been resolved, revealing how Integrator engages Pol II and coordinates 3'-end formation. This pathway is distinct from polyadenylation-dependent termination and highlights the diversity of GO:0006369 mechanisms.
Promoter-proximal termination and gene regulation
In simple terms: Sometimes the polymerase is stopped very early, which helps control how much RNA is made.
Promoter-proximal RNA polymerase II termination regulates transcription during human cell type transition. This early termination can act as a checkpoint that limits productive elongation and shapes gene expression programs. Together with elongation rate measurements, these findings link GO:0006369 to dynamic regulation of transcription.
Key Genes Involved in GO:0006369 termination of RNA polymerase II transcription
The following genes and proteins are central to termination of RNA polymerase II transcription (GO:0006369) based on the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| POLR2A | Encodes the largest subunit of RNA polymerase II, including the CTD that coordinates termination | Core target for studying Pol II release and CTD-dependent termination |
| SPT5 | Stabilizes RNA polymerase II and orchestrates transcription cycles, including termination | Key factor for elongation-to-termination transition |
| SPT4 | Forms a complex with SPT5 to regulate Pol II processivity and termination | Genetic model for dissecting SPT4/SPT5 functions |
| XRN2 | 5'-3' exonuclease implicated in polyadenylation-dependent termination | Functional target for testing the torpedo model |
| CPSF | Cleavage and polyadenylation specificity factor required for RNA 3'-end formation | Links RNA processing to termination |
| CstF | Cleavage stimulation factor involved in polyadenylation-coupled termination | Component of the 3'-end processing machinery |
| INTS11 | Integrator subunit required for snRNA termination | Structural and functional studies of Integrator-dependent termination |
| INTS9 | Integrator subunit involved in Pol II termination at snRNA genes | Target for Integrator-dependent termination assays |
| INTS4 | Integrator subunit contributing to termination | Component of the Integrator complex |
| RPB1 | Alternative name for the largest Pol II subunit; CTD phosphorylation regulates termination | Phospho-CTD status as a termination marker |
| RPB2 | Second largest Pol II subunit; part of the elongation complex | Structural studies of termination complexes |
| CTD | C-terminal domain of RPB1 that recruits termination and processing factors | Central regulatory hub for termination |
| XRN1 | Related exonuclease with roles in RNA turnover | Comparative studies of nuclease function |
| SPT6 | Elongation factor that can influence termination | Genetic interaction studies with SPT5 |
| PAPOLA | Poly(A) polymerase involved in 3'-end formation | Coupling of polyadenylation to termination |
| CPSF73 | Cleavage factor subunit | Target for cleavage-coupled termination assays |
| CPSF100 | Cleavage factor subunit | Component of the polyadenylation machinery |
| WDR33 | Polyadenylation factor | Accessory factor in 3'-end formation |
How Is termination of RNA polymerase II transcription Regulated?
Termination of RNA polymerase II transcription is regulated at multiple levels. The phosphorylation state of the RPB1 C-terminal domain controls recruitment of 3'-end processing and termination factors. SPT5 stabilizes Pol II and orchestrates transcription cycles, and its levels or modifications can influence termination efficiency. Promoter-proximal termination is regulated during human cell type transitions, indicating that developmental signals can modulate early termination. DNA-directed termination provides a sequence-encoded regulatory route that can act independently of polyadenylation. Integrator-dependent termination is regulated by the assembly and activity of the Integrator complex at snRNA genes. Kinetic measurements of gene-specific Pol II elongation rates show that termination timing is influenced by elongation rate.
termination of RNA polymerase II transcription and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SPT5 | Transcription cycle dysregulation | Knockout and point-mutation cell models |
| INTS11 | snRNA gene expression defects | Knockout and tagged knock-in models |
| XRN2 | Polyadenylation-coupled termination defects | Knockout and overexpression models |
| POLR2A | Global transcription termination defects | Point-mutation knock-in of CTD residues |
| CPSF | RNA 3'-end processing defects | Knockout and rescue models |
Termination defects and altered gene expression programs
Because termination defines the 3' boundary of transcription units, defects can cause read-through and altered gene expression. Promoter-proximal termination regulates transcription during human cell type transition, and its dysregulation could perturb developmental gene programs. Genetic dissection of the Pol II transcription cycle provides a framework for linking termination factor mutations to expression phenotypes.
Integrator-dependent termination and snRNA gene expression
Integrator-dependent termination is required for snRNA gene expression, and disruption of this pathway would impair snRNA production. Structural insights into Integrator-dependent termination provide a basis for interpreting disease-associated mutations in Integrator subunits. This links GO:0006369 to RNA processing disorders more broadly.
DNA-directed termination and genome stability
DNA-directed termination of mammalian RNA polymerase II can release Pol II at specific DNA elements. Failure of such termination could lead to transcriptional interference and genome instability. These mechanisms are relevant to diseases in which transcription and genome maintenance are perturbed.
From termination of RNA polymerase II transcription-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a termination factor essential for cell viability? | CRISPR knockout cell model |
| Does a specific residue control termination? | Point-mutation knock-in cell model |
| Where does a termination factor localize? | Tagged knock-in cell model |
| Does overexpression alter termination efficiency? | Overexpression cell model |
| Which genes are sensitive to termination defects? | CRISPR library screening |
| How does termination affect RNA 3'-end formation? | RNA-seq and 3'-end sequencing |
How to Study the termination of RNA polymerase II transcription Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Kinetic elongation assay | Gene-specific Pol II elongation rates | Determining when termination occurs |
| RNA-seq | Transcript abundance and read-through | Detecting termination defects |
| 3'-end sequencing | RNA 3'-end formation | Mapping polyadenylation and termination sites |
| Structural biology | Integrator-Pol II complex architecture | Understanding Integrator-dependent termination |
| In vitro termination assay | DNA-directed Pol II release | Testing DNA elements that trigger termination |
| CRISPR knockout | Loss-of-function phenotypes | Testing essentiality of termination factors |
| CRISPR point mutation | Residue-specific functions | Dissecting CTD and factor domains |
| Overexpression | Gain-of-function effects | Testing sufficiency of termination factors |
Measuring Pol II elongation and termination kinetics
Kinetic measurement of gene-specific RNA polymerase II transcription elongation rates provides quantitative data on when termination occurs. These assays can be combined with perturbation of termination factors to determine their effects on elongation and release. Such measurements are essential for distinguishing initiation, elongation, and termination defects.
RNA 3'-end mapping and transcriptome analysis
RNA-seq and 3'-end sequencing can detect read-through transcripts and altered 3'-end formation caused by termination defects. These methods are used to test whether a candidate factor is required for proper termination. They also reveal promoter-proximal termination events.
Structural and biochemical assays of termination complexes
Structural studies of Integrator-dependent termination have revealed how the complex engages Pol II. Biochemical assays can reconstitute DNA-directed termination and measure Pol II release. These approaches define the molecular requirements for GO:0006369.
Genetic dissection of the transcription cycle
Genetic dissection of the RNA polymerase II transcription cycle allows assignment of termination functions to specific factors. CRISPR-based perturbation enables testing of these factors in human cells. Combined with expression profiling, this approach links genotype to termination phenotype.
How CRISPR Can Be Used to Study GO:0006369 termination of RNA polymerase II transcription
Knockout
CRISPR knockout of termination factors such as SPT5, XRN2, or Integrator subunits can reveal whether they are required for GO:0006369. Knockout cell models are used to test viability and to measure read-through transcripts by RNA-seq. These models help distinguish essential from redundant termination pathways.
Point Mutation
Point-mutation knock-in can be used to test specific residues in Pol II CTD or in termination factors. For example, mutations in RPB1 CTD phosphorylation sites can be introduced to test their role in recruiting termination machinery. This approach provides mechanistic insight beyond simple loss-of-function.
Knock-in
Tagged knock-in of termination factors enables localization and interaction studies in live cells. Knock-in of reporter constructs can also be used to monitor termination at specific genes. These models are valuable for linking factor dynamics to termination.
Overexpression
Overexpression of termination factors can test whether increased levels alter termination efficiency or cause premature termination. Overexpression models are useful for gain-of-function studies of SPT5 and Integrator subunits. They complement knockout approaches to define sufficiency and dosage effects.
How EDITGENE Supports termination of RNA polymerase II transcription Research
Researchers studying termination of RNA polymerase II transcription-related genes often need to determine whether a candidate gene is causally involved in the process or merely correlated with it. CRISPR-based models provide a direct way to test causality by introducing defined genetic changes and measuring termination phenotypes. EDITGENE provides a suite of services to generate such models and to analyze the resulting data.
Contact EDITGENE today to design your custom CRISPR model for termination of RNA polymerase II transcription research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| SCAF8 Knockout HEK293 Cell Line | EDJ-KQ7690 | Human | 22828 | Details Get a Quote |
| SETX Knockout HEK293 Cell Line | EDJ-KQ7804 | Human | 23064 | Details Get a Quote |
| SSU72L1 Knockout HEK293 Cell Line | EDJ-KQ15518 | Human | 390033 | Details Get a Quote |
| SSU72L2 Knockout HEK293 Cell Line | EDJ-KQ15519 | Human | 390031 | Details Get a Quote |
| SSU72L3 Knockout HEK293 Cell Line | EDJ-KQ15520 | Human | 143506 | Details Get a Quote |
| SSU72L4 Knockout HEK293 Cell Line | EDJ-KQ15521 | Human | 441584 | Details Get a Quote |
| SSU72L5 Knockout HEK293 Cell Line | EDJ-KQ15522 | Human | 196120 | Details Get a Quote |
| SSU72L6 Knockout HEK293 Cell Line | EDJ-KQ15523 | Human | 136157 | Details Get a Quote |
| SCAF8 Knockout A-549 Cell Line | EDJ-KQ33060 | Human | 22828 | Details Get a Quote |
| SCAF8 Knockout HCT 116 Cell Line | EDJ-KQ33061 | Human | 22828 | Details Get a Quote |
| SCAF8 Knockout HeLa Cell Line | EDJ-KQ33062 | Human | 22828 | Details Get a Quote |
| SETX Knockout A-549 Cell Line | EDJ-KQ33319 | Human | 23064 | Details Get a Quote |
| SETX Knockout HCT 116 Cell Line | EDJ-KQ33320 | Human | 23064 | Details Get a Quote |
| SETX Knockout HeLa Cell Line | EDJ-KQ33321 | Human | 23064 | Details Get a Quote |
| SSU72L2 Knockout HCT 116 Cell Line | EDJ-KQ45109 | Human | 390031 | Details Get a Quote |
- 1
- 2
- Next Page »
Frequently Asked Questions About termination of RNA polymerase II transcription
What is GO:0006369?
GO:0006369 is the Gene Ontology term for termination of RNA polymerase II transcription, the process that completes production of a primary RNA polymerase II transcript.
What happens during termination of RNA polymerase II transcription?
During termination, Pol II stops RNA synthesis, the transcript is released, and the polymerase dissociates from DNA, often coupled to RNA 3'-end formation.
What genes are involved in termination of RNA polymerase II transcription?
Key genes include POLR2A, SPT5, SPT4, XRN2, CPSF subunits, CstF subunits, and Integrator subunits such as INTS11.
How is termination of RNA polymerase II transcription regulated?
It is regulated by CTD phosphorylation, SPT5, promoter-proximal termination signals, DNA-directed elements, and Integrator activity.
What is the difference between polyadenylation-dependent and DNA-directed termination?
Polyadenylation-dependent termination is coupled to RNA cleavage and polyadenylation, while DNA-directed termination is triggered by specific DNA elements and can occur independently of polyadenylation.
What is Integrator-dependent termination?
Integrator-dependent termination is a pathway in which the Integrator complex promotes Pol II termination at snRNA genes.
Why is promoter-proximal termination important?
Promoter-proximal termination regulates transcription during human cell type transitions and can act as an early checkpoint.
How can I study termination of RNA polymerase II transcription in the lab?
Common methods include kinetic elongation assays, RNA-seq, 3'-end sequencing, structural biology, and CRISPR perturbation.
What CRISPR models are useful for studying GO:0006369?
Knockout, point-mutation, knock-in, tagged knock-in, and overexpression models are all useful for testing termination factor function.
Does termination of RNA polymerase II transcription relate to disease?
Yes, defects in termination can alter gene expression programs and are linked to developmental and disease phenotypes.
Conclusion
Termination of RNA polymerase II transcription (GO:0006369) is a multi-step process that completes Pol II transcripts and is coupled to RNA 3'-end formation. It involves polyadenylation-dependent and DNA-directed pathways, as well as Integrator-dependent termination at snRNA genes. Key factors include SPT5, XRN2, CPSF/CstF, and Integrator subunits. CRISPR-based models provide a powerful way to test the causal roles of these factors in human cells. Understanding GO:0006369 is essential for interpreting gene expression programs and for identifying therapeutic targets in diseases linked to transcription dysregulation.
References
- 1. Eaton JD et al.. 2020. Termination of Transcription by RNA Polymerase II: BOOM!. Trends Genet 36(9):664-675 PMID: 32527618
- 2. Han Z et al.. 2023. DNA-directed termination of RNA polymerase II transcription.. Mol Cell 83(18):3253-3267.e7 PMID: 37683646
- 3. Fianu I et al.. 2024. Structural basis of Integrator-dependent RNA polymerase II termination.. Nature 629(8010):219-227 PMID: 38570683
- 4. Davidson L et al.. 2024. DNA-directed termination of mammalian RNA polymerase II.. Genes Dev 38(21-24):998-1019 PMID: 39496457
- 5. Hu S et al.. 2021. SPT5 stabilizes RNA polymerase II, orchestrates transcription cycles, and maintains the enhancer landscape.. Mol Cell 81(21):4425-4439.e6 PMID: 34534457
- 6. Liu H et al.. 2025. Kinetic measurement of gene-specific RNA polymerase II transcription elongation rates.. Genome Res 35(11):2550-2562 PMID: 41125442
- 7. Lysakovskaia K et al.. 2025. Promoter-proximal RNA polymerase II termination regulates transcription during human cell type transition.. Nat Struct Mol Biol 32(6):995-1005 PMID: 39934431
- 8. Chou SP et al.. 2022. Genetic dissection of the RNA polymerase II transcription cycle.. Elife 11 PMID: 35775732
